Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14035482 | 1.00 | MEN1 (0.59) | MEN1KMT2AKCNH2KCNA5SLC6A4 | |
| SCHEMBL14035305 | 1.00 | MEN1 (0.59) | MEN1KMT2AKCNH2KCNA5SLC6A4 | |
| Hydrochloric Acid SCHEMBL23211984 | 0.98 | MEN1 (0.58) | MEN1KMT2AKCNH2KCNA5SLC6A4 | |
| SCHEMBL30330107 | 0.84 | SLC6A2 (0.48) | MEN1KMT2AKCNH2KCNA5SLC6A4 | |
| SCHEMBL16121132 | 0.83 | CYP2D6 (0.41) | MEN1KMT2AKCNH2KCNA5SLC6A4 | |
| SCHEMBL31010334 | 0.81 | KCNA5 (0.57) | MEN1KMT2AKCNH2KCNA5CYP2D6 | |
| Hydrochloric Acid SCHEMBL7405456 | 0.80 | KCNA5 (0.55) | MEN1KMT2AKCNH2KCNA5CYP2D6 | |
| SCHEMBL6926672 | 0.79 | CYP2D6 (0.59) | MEN1KMT2AKCNH2KCNA5SLC6A4 | |
| SCHEMBL4094666 | 0.78 | HRH3 (0.42) | MEN1KMT2AKCNH2KCNA5SLC6A4 | |
| SCHEMBL4099833 | 0.78 | HRH3 (0.42) | MEN1KMT2AKCNH2KCNA5SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230104936-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| EP-3503888-A1 | INHIBITORS OF-BCR-ABL MUTANTS AND USE THEREOF | The Regents of The University of Michigan (US) | 2019-07-03 | — | — | EP | disclosed |
| US-10196378-B2 | Inhibitors of BCR-ABL mutants and use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-02-05 | — | — | US | disclosed |
| WO-2018039467-A1 | INHIBITORS OF-BCR-ABL MUTANTS AND USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-03-01 | — | — | WO | disclosed |
| US-20180057479-A1 | Inhibitors of BCR-ABL Mutants and Use Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2018-03-01 | — | — | US | disclosed |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-9737533-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals. Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| CN-102282136-B | Process for the preparation of rosuvastatin | KRKA TOVARNA ZDRAVIL D D NOVO | 2014-12-17 | — | — | CN | disclosed |
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| WO-2008134036-A1 | ALPHA-SUBSTITUTED ARYLMETHYL PIPERAZINE PYRAZOLO[1,5-α]PYRIMIDINE AMIDE DERIVATIVES | PANACOS PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | THPO, DPYD, TPMT | MEN1 4695/4885KMT2A 3485/4885KCNH2 2039/4885 |
| US-20180057479-A1 | Inhibitors of BCR-ABL Mutants and Use Thereof | ABL1, BCR, ABL2 | MEN1 4375/4885KMT2A 848/4885KCNH2 4336/4885 |
| US-20230104936-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | MEN1 782/4885KMT2A 2892/4885KCNH2 127/4885 |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | GRM2, GRM1, GRIN2C | MEN1 4777/4885KMT2A 988/4885KCNH2 1004/4885 |
| US-10196378-B2 | Inhibitors of BCR-ABL mutants and use thereof | ABL1, BCR, ABL2 | MEN1 4375/4885KMT2A 848/4885KCNH2 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.